Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalSTU:IC7 80 EBITDA Margin % is 16.56% as of Jun. 2026, which is 35% above its 10-year median of 12.30. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 814 Medical Devices & Instruments companies, ICU Medical ranks better than 61.06% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ICU Medical's EBITDA for the
three
months ended in Jun. 2026 was €79 Mil. ICU Medical's Revenue for the
three
months ended in Jun. 2026 was €479 Mil. Therefore, ICU Medical's EBITDA margin for the quarter that ended in Jun. 2026 was 16.56%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ICU Medical EBITDA Margin % Related Terms
ICU Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ICU Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IC7 vs NVST, MMSI, MMED: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ICU Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (STU:IC7) has a EBITDA Margin % of 16.56% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ICU Medical and its competitors. This is 35% above median its historical median of 12.30. Over the past decade, ICU Medical's EBITDA Margin % has ranged from 6.99 to 27.50. According to the industry distribution chart, ICU Medical ranks #317 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 38.9%.
Is ICU Medical's EBITDA Margin % too high?
ICU Medical's current EBITDA Margin % of 16.56% is 35% above median its 10-year median of 12.30. Over the past 10 years, this metric has ranged from a low of 6.99 to a high of 27.50. The Medical Devices & Instruments industry median EBITDA Margin % is 7.63. ICU Medical's value of 16.56% is 117.2% above this industry median. Based on the distribution chart, ICU Medical ranks #317 out of 814 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's EBITDA Margin % compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #317 out of 814 companies for EBITDA Margin %. This puts ICU Medical in the upper half of its industry. The industry median EBITDA Margin % is 7.63. ICU Medical's value of 16.56% is 117.2% above this benchmark. Historically, ICU Medical's own EBITDA Margin % has ranged from 6.99 to 27.50 over the past decade. While the company's 10-year median is 12.30 vs. the industry median of 7.63, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.63, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current EBITDA Margin % of 16.56% is 117.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ICU Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current EBITDA Margin % is 16.56%, which is 35% above median its own 10-year median of 12.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current EBITDA Margin % is 16.56%, which is 35% above median its 10-year median of 12.30 and 117.2% above the Medical Devices & Instruments industry median of 7.63. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current EBITDA Margin % is 16.56% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (STU:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for STU:IC7:
EBITDA Margin %: 16.56% (35% above median its 10-year median of 12.30)
GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
Industry Position: 117.2% above the Medical Devices & Instruments median (#317 of 814)
No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score
Get the complete analysis for STU:IC7
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IC7 has been successfully added to your 
